JP2021527692A - Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法 - Google Patents

Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法 Download PDF

Info

Publication number
JP2021527692A
JP2021527692A JP2020570933A JP2020570933A JP2021527692A JP 2021527692 A JP2021527692 A JP 2021527692A JP 2020570933 A JP2020570933 A JP 2020570933A JP 2020570933 A JP2020570933 A JP 2020570933A JP 2021527692 A JP2021527692 A JP 2021527692A
Authority
JP
Japan
Prior art keywords
alkyl
compound
substituted
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570933A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019246454A5 (https=
JP2021527692A5 (https=
Inventor
ダグラス ダブリュ． ボンハウス
ウォルフガング ジェイ． ウラシドロ
エミリー エム． ストッキング
スリニバサ レディ ナタラ
Original Assignee
ニューロポア セラピーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロポア セラピーズ インコーポレイテッド filed Critical ニューロポア セラピーズ インコーポレイテッド
Publication of JP2021527692A publication Critical patent/JP2021527692A/ja
Publication of JPWO2019246454A5 publication Critical patent/JPWO2019246454A5/ja
Publication of JP2021527692A5 publication Critical patent/JP2021527692A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020570933A 2018-06-20 2019-06-20 Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法 Pending JP2021527692A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862687733P 2018-06-20 2018-06-20
US62/687,733 2018-06-20
US201862752265P 2018-10-29 2018-10-29
US62/752,265 2018-10-29
PCT/US2019/038328 WO2019246454A1 (en) 2018-06-20 2019-06-20 Method of treating a condition associated with neurodegeneration using inhibitors of oat3

Publications (3)

Publication Number Publication Date
JP2021527692A true JP2021527692A (ja) 2021-10-14
JPWO2019246454A5 JPWO2019246454A5 (https=) 2022-06-27
JP2021527692A5 JP2021527692A5 (https=) 2022-06-27

Family

ID=67211909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570933A Pending JP2021527692A (ja) 2018-06-20 2019-06-20 Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法

Country Status (5)

Country Link
US (1) US20210290597A1 (https=)
EP (1) EP3810133A1 (https=)
JP (1) JP2021527692A (https=)
CN (1) CN112512523A (https=)
WO (1) WO2019246454A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195431A1 (en) * 2020-03-25 2021-09-30 The Brigham And Women's Hospital, Inc. Inhaled xenon therapy in neurodegenerative disease
CN113777197B (zh) * 2021-09-16 2022-05-27 福州大学 一种同时测定桔霉素和1-羟基-2-萘甲酸的方法
WO2024112921A1 (en) * 2022-11-22 2024-05-30 Mcphs University Treatment of tartaric acid toxicity in dogs with probenecid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098851A1 (en) * 2001-06-04 2002-12-12 Institut Fiziologicheski Aktivnykh Veschestv Rossiyskov Akademii Nauk Derivatives 0f n,s-substitutions n'-1 [(hetero)aryl] alkyl-n'-[hetero) aryl] methyl isothioureas, method for producing salts and bases thereof, physiologically active n,s-substitutions n'-1 [(hetero)aryl] alkyl-n'-[hetero) aryl] methyl isothioureas, a pharmaceutical composition and curing method
WO2013175215A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
JP7277473B2 (ja) * 2017-10-30 2023-05-19 ニューロポア セラピーズ インコーポレイテッド 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法
JP2023076473A (ja) * 2017-03-08 2023-06-01 長江存儲科技有限責任公司 ３次元メモリデバイスのスルーアレイコンタクト構造

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279637A (en) * 1979-06-02 1981-07-21 Velsicol Chemical Corporation Herbicidal N-substituted 4-imidazolin-2-ones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098851A1 (en) * 2001-06-04 2002-12-12 Institut Fiziologicheski Aktivnykh Veschestv Rossiyskov Akademii Nauk Derivatives 0f n,s-substitutions n'-1 [(hetero)aryl] alkyl-n'-[hetero) aryl] methyl isothioureas, method for producing salts and bases thereof, physiologically active n,s-substitutions n'-1 [(hetero)aryl] alkyl-n'-[hetero) aryl] methyl isothioureas, a pharmaceutical composition and curing method
WO2013175215A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
JP2023076473A (ja) * 2017-03-08 2023-06-01 長江存儲科技有限責任公司 ３次元メモリデバイスのスルーアレイコンタクト構造
JP7277473B2 (ja) * 2017-10-30 2023-05-19 ニューロポア セラピーズ インコーポレイテッド 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. NEURAL. TRANSM. (VIENNA), vol. 116, no. 9, JPN6023026724, 2009, pages 1079 - 1086, ISSN: 0005269742 *
日薬理誌, vol. 122, no. 1, JPN6023026723, 2003, pages 55 - 64, ISSN: 0005095406 *

Also Published As

Publication number Publication date
EP3810133A1 (en) 2021-04-28
WO2019246454A1 (en) 2019-12-26
US20210290597A1 (en) 2021-09-23
CN112512523A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
US10954198B2 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
JP6783900B2 (ja) タンパク質凝集の阻害剤としてのヘテロアリールアミド
JP2021527112A (ja) ニューロキニン−１受容体アンタゴニストとしての化合物およびその使用
US20230391734A1 (en) Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
JP2021527692A (ja) Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法
JP2015515465A (ja) タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体
CN112313230B (zh) 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物
TWI725041B (zh) 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
EA042432B1 (ru) Замещенные фенилсульфонил фенилтриазолтионы и их применение
WO2016040780A1 (en) Aminomethyl- and methyloxy-linked tricyclic compounds as inhibitors of protein aggregation
BR112015016433B1 (pt) Uso de um composto de formula (i) para tratar um disturbio associado com a tensão do dobramento incorreto da proteína
JPWO2019146670A1 (ja) 光応答性Ｓｍｏｏｔｈｅｎｅｄリガンド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230628

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240227